Krista Fogarty
Known title: Principal Accounting OfficerCIK: 0001906986
Krista Fogarty's purchase track record
Krista Fogarty has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/17/2022 | LPCN | $11K | -31.2% | -54.9% | -2.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| LPCN | ▲ Buy | Grant | 991 | $0 | 3/8/2024 | View on chart |
| LPCN | ▲ Buy | Open Market | 12,500 | $11K | 5/17/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Lipocine Partner Verity Gets Health Canada Approval for TLANDO
Lipocine's licensing partner, Verity Pharmaceuticals, received Health Canada approval for TLANDO capsules used in testosterone replacement therapy. This regulatory milestone is relevant to Lipocine as it validates the commercial potential of the licensed product. The stock is currently trading near its 52-week high, reflecting strong recent momentum.
Lipocine Partner Verity Gets Health Canada Approval for TLANDO. Lipocine's licensing partner, Verity Pharmaceuticals, received Health Canada approval for TLANDO capsules used in testosterone replacement therapy. This regulatory milestone is relevant to Lipocine as it validates the commercial potential of the licensed product. The stock is currently trading near its 52-week high, reflecting strong recent momentum.